title: Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease.
abstract: Due to the fact that an increased number of patients have experienced bloodstream infections caused by Candida species and the high mortality of this infection, there is a need for a strategy to reduce this scenery. One possible strategy is the use of new drugs, such as fructose-1,6-bisphosphate (FBP), which is a high-energy glycolytic metabolite and has shown to have therapeutic effects in several pathological conditions such as ischemia, shock, toxic injuries, and bacterial sepsis. The aim of this manuscript was to determine the role of FBP in experimental Candida albicans bloodstream infection. We used mice that were divided into three experimental groups: sham (not induced), bloodstream infection (induced with intratracheal instillation of C. albicans) and FBP (bloodstream infection plus FBP 500 mg/kg i.p.). Blood was taken for assessment of complete hematological profile and cytokine assay (IL-6 and MCP-1). Results of the study demonstrated that mortality decreased significantly in groups that received FBP. All cytokine and hematological indexes of FBP group were similar to bloodstream infection group with exception of platelets count. FBP significantly prevented the decrease in platelets. Taken together, our results demonstrate that FBP prevented the mortality in C. albicans bloodstream infection.
authors.affiliation: Laboratório de Microbiologia Clínica, Ciências da Saúde, Centro Universitário Franciscano, UNIFRA, Rua dos Andradas 1614, sala 115, 97010-032, Santa Maria, Rio Grande do Sul, Brazil. roberto@unifra.br
authors.forename: Roberto Christ Vianna
authors.initials: RC
authors.lastname: Santos
authors.forename: Rafael Noal
authors.initials: RN
authors.lastname: Moresco
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Peña Rico
authors.forename: Antonio R García
authors.initials: AR
authors.lastname: Susperregui
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Rosa
authors.forename: Ramon
authors.initials: R
authors.lastname: Bartrons
authors.forename: Francesc
authors.initials: F
authors.lastname: Ventura
authors.forename: Débora Nunes
authors.initials: DN
authors.lastname: Mário
authors.forename: Sydney Hartz
authors.initials: SH
authors.lastname: Alves
authors.forename: Etiane
authors.initials: E
authors.lastname: Tatsch
authors.forename: Helena
authors.initials: H
authors.lastname: Kober
authors.forename: Ricardo Obalski
authors.initials: RO
authors.lastname: de Mello
authors.forename: Patrícia
authors.initials: P
authors.lastname: Scherer
authors.forename: Henrique Bregolin
authors.initials: HB
authors.lastname: Dias
authors.forename: Jarbas Rodrigues
authors.initials: JR
authors.lastname: de Oliveira
mesh_terms: D000818:Animals; D002176:Candida albicans / Q000187:drug effects; D058387:Candidemia / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality*; D018932:Chemokine CCL2 / Q000097:blood; D005635:Fructosediphosphates / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D051379:Mice; D010976:Platelet Count
chemical_list: C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D005635:Fructosediphosphates; D015850:Interleukin-6; C029063:fructose-1,6-diphosphate